PLRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
PLIANT THERAPEUTICS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$0.90−0.00 (-0.13%)
Close on Oct 19, 2026
- Market cap
- $55.65M
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Share price
−$0.6713 (−42.76%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
PLIANT THERAPEUTICS, INC. reported revenue of $0 for fiscal 2025. Free cash flow was -$70.90M.
Revenue
$0
FY2025
Operating income
-$97.48M
TTM Q2 2026
Free cash flow
-$70.90M
TTM Q2 2026
EPS, diluted
-$1.49
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $55.65M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.38
- Dividend yield
- 0.00%
- Free cash flow yield
- -127.40%
Fundamentals
- Revenue
- $0
- Net income
- -$92.29M
- EPS, diluted
- -$1.49
- Free cash flow
- -$70.90M
- Book value per share
- $2.37
- Diluted shares
- 62M
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
–
Operating income
-$97.48M
Net income
-$92.29M
EPS, diluted
-$1.49
Free cash flow
-$70.90M
Reported periodTrailing twelve months